Managing Director & Senior Partner
Srikant Vaidyanathan joined Boston Consulting Group in 2003 and has worked in the Chicago and Zurich offices. He is a core member of the firm’s Health Care; Marketing, Sales & Pricing; and Operations practices. He leads BCG’s market access and pricing sector worldwide and is an expert in technial operations across the value chain in both small molecules and biologics.
Before joining BCG, Srikant worked at Corning in the US for five years. While there, he took several products from concept to market. He has contributed to publications from the Health Care and People & Organization practices.
To become leaders in the field, biopharma companies must understand unmet needs and evolving standards of care and make greater use of real-world evidence.
Contrary to what skeptics believe, it’s not necessary to go all in when applying agile methods. A selective approach can promote efficiency and effectiveness.
With advances in knowledge, understanding, technology, and data come fragmentation and complexity. Since the bets are big, companies need to evaluate prospects and make their investments count.
Multinational companies need to map a strategy to tap into China’s growth—and compete with increasingly innovative “homegrown” Chinese biopharma companies.
Even highly regulated and rigid industries can benefit from new ways of working.
The country gets its shine from a strong job market—but new immigration policies have eroded its star standing.